Skip to content
10-K

Annual Report

Matinas BioPharma Holdings, Inc. MTNB

0001641172-25-004882

← back to feed
Filed
Apr 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Apr 15, 2025 5.09M sh
Shares Diluted restated FY 2024 · Dec 31, 2023 4.35M sh
Capex FY 2024 · Dec 31, 2023 $218K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$15.28M
Current Liabilities FY 2024 · Dec 31, 2023 $2.62M
Total Liabilities FY 2024 · Dec 31, 2023 $5.86M
Current Assets FY 2024 · Dec 31, 2023 $15.54M
Total Assets FY 2024 · Dec 31, 2023 $25.1M
Eps Diluted restated FY 2024 · Dec 31, 2023 −$5.28
Eps Basic restated FY 2024 · Dec 31, 2023 −$5.28
Sga Expense FY 2024 · Dec 31, 2023 $10.37M
Rd Expense FY 2024 · Dec 31, 2023 $14.49M
Net Income FY 2024 · Dec 31, 2023 −$22.94M
Operating Income FY 2024 · Dec 31, 2023 −$23.77M
Revenue FY 2024 · Dec 31, 2023 $1.1M
Cash And Equivalents FY 2024 · Dec 31, 2022 $6.83M
Stockholders Equity FY 2024 · Dec 31, 2022 $36.64M